Irish data analytics company Diaceutics has signed a $1 million contract with a global pharmaceutical company for its DXRX platform.
The value of the contract will be spread out across five years, covering multiple products and subject to certain milestones being met. Under the deal, Diaceutics will deliver customised data insights through the platform, with a set of real-world data and insights on lab test results that identify physicians who are treating patients in their target cohorts.
The deal also has the potential to set up future opportunities with the client.
"This multi-product, multi-year auto renew contract speaks to how our DXRX platform spans the full diagnostic commercialisation pathway; in this instance providing our client with the insights they need to better engage with prescribers to choose their therapy," said Ryan Keeling, cofounder and chief information officer of Diaceutics.
“We are encouraged by the pace of deal flow for our newly launched data feeds, which are proving valuable entry points for both new and existing customers onto the DXRX platform.”
